Leaders in Lung Cancer Research Recognized by LUNGevity
Honoring the next generation of oncology pioneers committed to making a difference in lung cancer treatment
LUNGevity Foundation, the leading nonprofit dedicated to lung cancer, has announced the recipients of their prestigious Career Development Awards for 2025. This program, established in 2012, has become a vital component in nurturing the careers of junior investigators dedicated to advancing lung cancer research.
Over the years, LUNGevity has provided substantial financial support to numerous researchers, issuing 43 Career Development Awards to date. These awards not only fund crucial research projects but also offer invaluable mentorship and training in science communication skills. The foundation emphasizes the importance of developing a robust oncology workforce to continue making advances in the fight against lung cancer.
"Today's research is tomorrow's cure," stated Upal Basu Roy, PhD, MPH, the Executive Director of LUNGevity Research. He conveyed a clear message about the necessity of fostering new scientific talent dedicated to revitalizing lung cancer treatment and improving survival rates for patients.
Among the awardees, one project earned the EGFR Resisters/LUNGevity Career Development Award, while another received the Lung Cancer Initiative-LUNGevity Career Development Award, highlighting projects aimed at significantly improving treatment for lung cancer patients.
A Look at the 2025 Award-winning Research Projects
Local CAR T Therapy for CNS Progression in NSCLC
Elliott Brea, MD, PhD
From Dana-Farber Cancer Institute, Dr. Brea received the EGFR Resisters/LUNGevity Research Award for his project focused on CAR-T cell therapy aimed at treating central nervous system (CNS) metastasis in patients with EGFR-positive non-small cell lung cancer (NSCLC).
With over half of patients developing CNS metastasis, Dr. Brea's team is engineering a specialized CAR-T cell therapy targeting TROP-2, a protein linked to both lung cancer and healthy cells. The project innovatively seeks to administer the treatment into the tumor site directly, thereby minimizing risks to surrounding healthy tissues. Enhancing treatment precision could transform CNS cancer management for EGFR-positive lung cancer patients.
"For many living with EGFR-positive lung cancer, CNS metastasis is a daunting challenge," shared Jill Feldman, co-founder of EGFR Resisters. She emphasized the importance of Dr. Brea's research in inspiring hope for more effective treatments in the future.
Understanding Drug Tolerance in EGFR Mutant LUAD
Esther Redin, PhD
At Memorial Sloan Kettering Cancer Center, Dr. Redin's research, supported by the Lung Cancer Initiative-LUNGevity Career Development Award, investigates the mechanisms behind drug tolerance in lung adenocarcinoma (LUAD).
Drug therapies targeting EGFR gene mutations initially succeed but often leave behind drug-tolerant persister cells that lead to tumor recurrence. Dr. Redin aims to unveil these survival mechanisms and develop strategies to counteract drug resistance, laying essential groundwork for future clinical trials designed to help EGFR-positive lung cancer patients.
Paige Humble, CEO of Lung Cancer Initiative, noted, "Understanding drug tolerance is crucial for patients facing lung cancer. Dr. Redin's research offers hope for developing effective treatments that combat resistance and achieve lasting results in patient care."
Enhancing Immunotherapy Responses in Lung Cancer
Gavitt Woodard, MD
Representing Yale University, Dr. Woodard's project explores the effects of STK11 mutations on immune response in lung cancer treatment.
Despite improvements in survival rates due to immunotherapy, a significant number of tumors do not respond to these therapies. Dr. Woodard will examine how genetic mutations may hinder T cell infiltration in tumors, focusing on a protein, PLA2G10, that obstructs T cell entry. By investigating this relationship, Dr. Woodard's research aspires to enhance immunotherapy effectiveness for those struggling with lung cancer.
Dr. Basu Roy conveyed, "Improving the effectiveness of immunotherapy can fundamentally change outcomes for countless individuals facing lung cancer. Dr. Woodard's research paves a path toward more effective treatments that can save lives."
The Impact of LUNGevity's Career Development Awards
Through these Career Development Awards, LUNGevity and several partners are investing in pioneering research projects that prioritize patient needs. This initiative is crucial for reshaping the landscape of lung cancer diagnosis and treatment.
These projects not only represent a commitment to scientific advancement but also underscore the importance of patient-centric research. As the award recipients embark on their research journeys, they will undoubtedly contribute to breakthroughs that could enhance the lives of many.
Frequently Asked Questions
What are LUNGevity's Career Development Awards?
LUNGevity's Career Development Awards support junior researchers in lung cancer, providing funding and mentorship to fuel innovation in treatment.
Who are the recipients of the 2025 awards?
Recipients include Drs. Elliott Brea, Esther Redin, and Gavitt Woodard, recognized for their significant research projects addressing lung cancer challenges.
What is the focus of Dr. Brea's research?
Dr. Brea's research focuses on developing CAR-T cell therapy to treat CNS metastasis in patients with EGFR-positive NSCLC.
How does Dr. Redin's project aim to combat drug resistance?
Dr. Redin aims to identify mechanisms of drug tolerance to develop strategies for eliminating persister cells in EGFR-positive lung cancer.
What are the broader goals of LUNGevity?
LUNGevity aims to transform lung cancer research and care by improving early detection, advancing treatments, and ensuring equitable access to care.
